Monolithic Zirconia Full-Arch Rehabilitation Using a Motion-Integrated Digital Workflow Combining M-4 and All-On-4 Protocols: A Clinical Report.

Int J ProsthodontSep 11, 2026
Case ReportGeneral Surgery

Mohamed I Alghraisi, Amr A El-Sawy, Rabia Dakhil et al.

✦ AI-curated · Sources linked

Case in brief

A 45-year-old edentulous woman underwent full-arch rehabilitation utilizing a digital workflow that integrated the M-4 protocol for the maxilla and the All-on-4 concept for the mandible. The use of dual-scan CBCT and facial scans allowed for precise prosthetic planning, while real-time jaw-motion data informed the occlusion design. Monolithic zirconia prostheses were successfully delivered on titanium multiunit abutments.

Diagnostic / clinical pearl

Incorporating real-time jaw-motion data into the design process can enhance the personalization of occlusion in full-arch rehabilitations.

Why it matters

This case highlights the effectiveness of a motion-integrated digital workflow in addressing both functional and aesthetic challenges in immediate full-arch rehabilitation.

Source

PubMed · PMID 41758697

Published in Int J Prosthodont. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.